Ocular Therapeutix Inc. (OCUL) Sees Unusually-High Trading Volume
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares saw strong trading volume on Friday . 522,255 shares changed hands during mid-day trading, a decline of 4% from the previous session’s volume of 546,577 shares.The stock last traded at $5.86 and had previously closed at $5.34.
Several equities research analysts recently issued reports on the stock. Morgan Stanley restated a “buy” rating on shares of Ocular Therapeutix in a research report on Saturday, April 9th. Cowen and Company restated a “buy” rating on shares of Ocular Therapeutix in a research report on Monday, June 6th. Zacks Investment Research cut shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $48.00 price objective on shares of Ocular Therapeutix in a research report on Sunday, April 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $31.85.
The company has a 50 day moving average of $7.59 and a 200 day moving average of $8.72. The company’s market cap is $147.11 million.
Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The firm earned $458 million during the quarter. Equities research analysts predict that Ocular Therapeutix Inc. will post ($1.86) earnings per share for the current fiscal year.
In other Ocular Therapeutix news, CEO Amarpreet Sawhney bought 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, June 9th. The stock was bought at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the purchase, the chief executive officer now owns 573,733 shares in the company, valued at approximately $3,844,011.10. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.